Login
$OVID
$2.44 +$0.04 (1.6%) After hours

$OVID 8-K/A SEC Filings

Filed On Filing
11 Aug 2021 8-K/A: Departure/Election of Directors or Officers; Compensation

On July 8, 2021, the Company filed the Original Filing disclosing that the Company’s Board of Directors (the “Board”) had appointed Dr. Robert Michael Poole as a director of the Company effective July 9, 2021. At the time of filing of th...

17 Jun 2019 8-K/A: Entry into a Material Definitive Agreement

[***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed.

28 Mar 2019 8-K/A: Departure/Election of Directors or Officers; Compensation; Other Events

NEW YORK – March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior m...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support